[ad_1]
The company aims to expand its team size in Singapore to 30 people by 2026, covering administrative, commercial, market access, medical affairs and quality assurance functions.
Daiichi Sankyo Singapore Company officially opened in Singapore on February 22, 2024.
As a subsidiary of Daiichi Sankyo, Daiichi Sankyo Singapore will work to address unmet needs in oncology with a view to extending and improving the lives of cancer patients; cancer accounts for almost 30% of all deaths in Singapore .
This Asia Pacific regional center will focus on antibody-drug conjugates (ADCs), a class of drugs that offer precise targeting and efficient drug delivery for certain tumor types, by delivering potent anti-cancer agents directly to cancer cells. Eliminate them while limiting the growth of cancer cells. Damage surrounding healthy cells.
respond to inquiries Office of Human Resources ManagementA spokesperson for Daiichi Sankyo said the team in Singapore is made up of administrative, commercial, market entry, medical affairs and quality assurance functions. The company aims to increase the number of employees in these functions to 30 people by 2026 to further support the company’s goal of providing faster services and innovation to cancer patients in Singapore.
Goh Wan Yee, Senior Vice President and Head of Healthcare, Singapore Economic Development BoardCommented: “Daiichi Sankyo’s decision to open an office in Singapore reflects our strength as a global center for biomedical sciences and will further enrich our ecosystem with precision treatment capabilities. We look forward to seeing what Daiichi Sankyo will see growth and efforts to launch new medicines that benefit patients around the world.”
Koichi Morino, Managing Director of Daiichi Sankyo Singapore, added: “Singapore is increasingly becoming an important global center for research and innovation in precision cancer treatments. Therefore, with our proprietary DXd ADC technology, we are pleased to be able to contribute to improving the treatment of cancer patients in Singapore.” contribute to treatment outcomes.
“We are committed to creating new employment and treatment opportunities in Singapore and look forward to working closely with relevant professionals and the patient community to launch new drug delivery methods.”
The newly established Research and Development, Pharmacovigilance and Quality Assurance (RDPV QA) function in Singapore as part of Daiichi Sankyo’s quality assurance organization “marks a strategic leap in strengthening the organization’s commitment to patients, customers and rigorous quality assurance” “In all its course.
Overall, the Asia Pacific Center will serve as a center of excellence, driving the mission of “Patients First, Quality Always” while aiming to ensure the highest quality standards in research and development, pharmacovigilance, medical affairs, and critical processes and systems across the region.
Daiichi Sankyo’s product portfolio currently consists of six DXd ADCs in clinical development for multiple cancers, one of which is currently commercialized.
Clue pictures/provided
[ad_2]
Source link